FIELD: medicine, pharmacy.
SUBSTANCE: treatment involves using the injection solution based on water-soluble prednisolon formulation containing sodium salt and accessory additive. Prednisolon sodium phosphate is used as prednisolon water-soluble formulation, and anhydrous sodium hydrogen phosphate and sodium dihydrogen phosphate dihydrate taken in the ratio = (1.375-1.5):1, respectively, are used as sodium salt, and propylene glycol is used as an additional additive in the following ratio of components, wt.-%: prednisolon sodium phosphate (as measured for prednisolon), 2.5-3.5; anhydrous sodium hydrogen phosphate, 0.045-0.055; sodium dihydrogen phosphate dihydrate, 0.03-0.04; propylene glycol, 12-17, and injection water, the balance, up to 100%. Invention can be used in producing hormonal preparation prednisolon in injection formulation for treatment of rheumatism, infectious nonspecific polyarthritis, bronchial asthma, leukemia and other diseases. Invention provides enhancing stability of prednisolon-containing solution and prolonged storage time.
EFFECT: improved and valuable properties of solution.
3 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
HUMAN INTERFERON-ALPHA-TWO AQUEOUS SOLUTION FOR INJECTION | 2002 |
|
RU2238758C2 |
EMULSION OF PERFLUOROORGANIC COMPOUNDS OF MEDICINAL INDICATION AND METHOD FOR ITS OBTAINING | 2004 |
|
RU2259819C1 |
METHOD FOR PRODUCTION OF TYLOSINE | 1993 |
|
RU2108392C1 |
HYDROXYETHYLCTLLULOSE PRODUCT AND METHOD OF PREPARATION THEREOF | 1999 |
|
RU2142961C1 |
COMBINATIONS FOR TREATING IMMUNO-INFLAMMATORY DISORDERS | 2002 |
|
RU2322984C2 |
EYE DROPS | 2010 |
|
RU2431470C1 |
COMPOSITION OF AQUEOUS SOLUTION OF RECOMBINANT HUMAN INTERFERON ALPHA-2 FOR RECTAL ADMINISTRATION | 2014 |
|
RU2564951C1 |
CONTACT LENS CARE SOLUTION | 2020 |
|
RU2755298C1 |
ENCAPSULATED LYPOSOMAL ANTIVIRAL AGENT BASED ON HUMAN INTERFERON ALPHA-2b FOR VAGINAL APPLICATION | 2014 |
|
RU2552851C1 |
METHOD OF PRODUCING ENZYMIC PREPARATION OF L-LYSINE-DECARBOXYLASE | 0 |
|
SU1433981A1 |
Authors
Dates
2005-06-27—Published
2004-07-02—Filed